Search

Your search keyword '"Talloen, W."' showing total 105 results

Search Constraints

Start Over You searched for: Author "Talloen, W." Remove constraint Author: "Talloen, W."
105 results on '"Talloen, W."'

Search Results

7. Safety, pharmakokinetics and antiviral activity of novel capsid assembly modulator (CAM) JNJ-56136379 (JNJ-6379) in treatmentnaive chronic hepatitis B (CHB) patients without cirrhosis

9. EEG Alpha Power as an Intermediate Measure between BDNF Val66Met and Depression Severity in Patients with Major Depressive Disorder

10. Association between COMT Val158Met genotype and EEG alpha peak frequency tested in two independent cohorts

15. 1167 PRE-TREATMENT IP-10 LEVELS AND IL28B GENOTYPE IN PREDICTION OF SVR IN PRIOR TREATMENT-EXPERIENCED GENOTYPE 1 HCV PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN IN THE REALIZE STUDY

23. Automated Spot Counting in Microbiology.

24. Viral sequence analysis of chronic hepatitis B patients treated with the capsid assembly modulator JNJ-56136379 in the JADE phase 2a study.

25. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection.

26. Drug-Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379 (Bersacapavir).

27. JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B.

28. Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection.

29. Mean HBsAg decline at week 24 of PEG-IFN-based treatment predicts subsequent rate of HBsAg clearance - suggesting a valuable endpoint for early development HBV trials.

30. Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers.

31. Virology analysis of chronic hepatitis B virus-infected patients treated for 28 days with JNJ-56136379 monotherapy.

32. JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection.

33. Correction to: Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects.

34. New Developments in Factor Score Regression: Fit Indices and a Model Comparison Test.

35. Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects.

36. Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection.

37. A bootstrap version of the Hausman test to assess the impact of cluster-level endogeneity beyond the random intercept model.

38. A random effects model for the identification of differential splicing (REIDS) using exon and HTA arrays.

39. Identification of the minimum effective dose for normally distributed data using a Bayesian variable selection approach.

40. Gait characteristics and spatio-temporal variables of climbing in bonobos (Pan paniscus).

41. Assessing moderated mediation in linear models requires fewer confounding assumptions than assessing mediation.

42. Weighted similarity-based clustering of chemical structures and bioactivity data in early drug discovery.

43. A joint modeling approach for uncovering associations between gene expression, bioactivity and chemical structure in early drug discovery to guide lead selection and genomic biomarker development.

44. High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity.

45. Integrating High-Dimensional Transcriptomics and Image Analysis Tools into Early Safety Screening: Proof of Concept for a New Early Drug Development Strategy.

46. Identification of in vitro and in vivo disconnects using transcriptomic data.

47. Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project.

48. ViVaMBC: estimating viral sequence variation in complex populations from illumina deep-sequencing data using model-based clustering.

49. Connecting gene expression data from connectivity map and in silico target predictions for small molecule mechanism-of-action analysis.

50. VirVarSeq: a low-frequency virus variant detection pipeline for Illumina sequencing using adaptive base-calling accuracy filtering.

Catalog

Books, media, physical & digital resources